Jay Gertz
@gertzlab.bsky.social
Shameless promotion of our amazing gene regulation/cancer epigenetics work
http://uofuhealth.utah.edu/huntsman/labs/gertz/
http://uofuhealth.utah.edu/huntsman/labs/gertz/
Reposted by Jay Gertz
Our new story is out in eLife! From the editorial assessment: "This landmark study elucidates the intricate structural mechanisms by which both covalent and non-covalent synthetic ligands can co-occupy the binding pocket of the #nuclearreceptor transcription factor PPARγ..." doi.org/10.7554/eLif...
Unanticipated mechanisms of covalent inhibitor and synthetic ligand cobinding to PPARγ
Commonly used covalent PPARγ inhibitors weaken, but do not block, binding of other ligands via an allosteric mechanism where ligands clash with a covalent ligand-induced transcriptionally repressive s...
doi.org
November 21, 2024 at 4:52 AM
Our new story is out in eLife! From the editorial assessment: "This landmark study elucidates the intricate structural mechanisms by which both covalent and non-covalent synthetic ligands can co-occupy the binding pocket of the #nuclearreceptor transcription factor PPARγ..." doi.org/10.7554/eLif...
Reposted by Jay Gertz
Looking forward to reconnecting at the International Adrenal Cancer Symposium in Houston! Excited to share new data with 2 talks & 2 posters on #WNT #senescence #androgens & #myeloid cells in #ACC. Hoping that someone in the #adrenal fan club might also appreciate our Halloween costume #hormones
November 21, 2024 at 8:29 PM
Looking forward to reconnecting at the International Adrenal Cancer Symposium in Houston! Excited to share new data with 2 talks & 2 posters on #WNT #senescence #androgens & #myeloid cells in #ACC. Hoping that someone in the #adrenal fan club might also appreciate our Halloween costume #hormones
Reposted by Jay Gertz
New #lobular breast cancer study from Sikora Lab is up, after buzz re: PARP inhibitors at #ILCSymposium!
We think ILC-specific co-reg fxn of MDC1 allows ER:MDC1 to control endo response/resistance in ILC, at the cost of a DNA repair dysfunction that can be hit with PARPi.
Thread: 1/8
We think ILC-specific co-reg fxn of MDC1 allows ER:MDC1 to control endo response/resistance in ILC, at the cost of a DNA repair dysfunction that can be hit with PARPi.
Thread: 1/8
Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breast https://www.biorxiv.org/content/10.1101/2023.10.29.564555v1
Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breast https://www.biorxiv.org/content/10.1101/2023.10.29.564555v1
Invasive lobular carcinoma of the breast (ILC) are typically estrogen receptor alpha (ER)-positive a
www.biorxiv.org
October 30, 2023 at 3:11 PM
New #lobular breast cancer study from Sikora Lab is up, after buzz re: PARP inhibitors at #ILCSymposium!
We think ILC-specific co-reg fxn of MDC1 allows ER:MDC1 to control endo response/resistance in ILC, at the cost of a DNA repair dysfunction that can be hit with PARPi.
Thread: 1/8
We think ILC-specific co-reg fxn of MDC1 allows ER:MDC1 to control endo response/resistance in ILC, at the cost of a DNA repair dysfunction that can be hit with PARPi.
Thread: 1/8
Reposted by Jay Gertz
No better way to understand the genetic basis of cancer than to work on chromatin variants. Our latest work provides insights into the role of repetitive DNA sequences as regulatory elements across pluripotent, mature, and cancer cells (slight focus on prostate cancer). Enjoy!
Transposable elements are co-opted as oncogenic regulatory elements by lineage-specific transcriptio...
Abstract. Transposable elements hold regulatory functions that impact cell fate determination by controlling gene expression. However, little is known about the transcriptional machinery engaged at tr...
aacrjournals.org
September 11, 2023 at 5:53 PM
No better way to understand the genetic basis of cancer than to work on chromatin variants. Our latest work provides insights into the role of repetitive DNA sequences as regulatory elements across pluripotent, mature, and cancer cells (slight focus on prostate cancer). Enjoy!
Reposted by Jay Gertz
Dynamite work from @profriggins.bsky.social for the first @biorxiv-cancer.bsky.social post!!! ER+ =/= ER+/HER2+ and the latter needs distinct attention when considering how tumors resist anti-estrogen therapy.
Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer https://www.biorxiv.org/content/10.1101/2023.08.21.554116v1
August 23, 2023 at 7:49 PM
Dynamite work from @profriggins.bsky.social for the first @biorxiv-cancer.bsky.social post!!! ER+ =/= ER+/HER2+ and the latter needs distinct attention when considering how tumors resist anti-estrogen therapy.
Since I just got over to Bluesky (Hi!), this story is a couple of days old. Nice writeup about Zannel Blanchard's final study in the lab: healthcare.utah.edu/huntsmancanc...
Estrogen Receptor Mutation Study Suggests Potential Treatments for Endometrial Cancers
Huntsman Cancer Institute researchers studied estrogen receptor mutations and its connections to endometrial cancer. The findings led to the identification of potential personalized treatments for a c...
healthcare.utah.edu
August 23, 2023 at 4:21 PM
Since I just got over to Bluesky (Hi!), this story is a couple of days old. Nice writeup about Zannel Blanchard's final study in the lab: healthcare.utah.edu/huntsmancanc...